Pakfetrat Atessa, Talebi Mehdi, Dalirsani Zohreh, Mohajeri Ahmad, Zamani Roya, Ghazi Ala
Oral and Maxillofacial Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Family Medicine Department, Faculty of Psychiatry, Mashhad University of Medical Sciences, Mashhad, Iran.
Avicenna J Phytomed. 2019 Nov-Dec;9(6):505-516. doi: 10.22038/AJP.2019.12764.
Burning mouth syndrome (BMS) is a debilitating disorder with few limited treatment modalities. Because of the proven association between BMS symptoms, and depression and anxiety, treatment modalities that alleviate the two latter etiologic factors can be clinically effective. Thus, owing to the antidepressant and potential analgesic effects of crocin (as an active constituent of saffron), the present study was performed to compare the effect of crocin and citalopram (as control) on BMS symptoms and depression/anxiety in patients with BMS.
The present double-blind randomized clinical trial was carried out on BMS patients. Patients were randomly divided into citalopram (n=21) and crocin (n=26) groups and treated for 11 weeks. BMS symptoms (based on Visual Analysis Scale (VAS)), as well as anxiety and depression (based on Hamilton questionnaire) were evaluated at baseline and during the treatment period. Mann-Whitney, Chi-Square test, Independent t-test, Friedman, and Spearman correlation were employed for statistical analysis.
Our findings showed a significant effect for crocin on the severity of BMS symptoms, anxiety and depression in BMS patients.
Crocin can be considered for treatment of BMS subjects with concurrent anxiety and/or depression.
灼口综合征（BMS）是一种使人衰弱的疾病，治疗方式有限。由于已证实BMS症状与抑郁和焦虑之间存在关联，缓解后两种病因的治疗方式可能具有临床疗效。因此，鉴于西红花苷（作为藏红花的一种活性成分）具有抗抑郁和潜在的镇痛作用，本研究旨在比较西红花苷和西酞普兰（作为对照）对BMS患者BMS症状及抑郁/焦虑的影响。
本双盲随机临床试验在BMS患者中开展。患者被随机分为西酞普兰组（n = 21）和西红花苷组（n = 26），并接受为期11周的治疗。在基线期和治疗期间评估BMS症状（基于视觉分析量表（VAS））以及焦虑和抑郁（基于汉密尔顿问卷）。采用曼-惠特尼检验、卡方检验、独立样本t检验、弗里德曼检验和斯皮尔曼相关性分析进行统计分析。
我们的研究结果表明，西红花苷对BMS患者的BMS症状严重程度、焦虑和抑郁有显著影响。
对于伴有焦虑和/或抑郁的BMS患者，可考虑使用西红花苷进行治疗。
